Developing Malaysian biotechnology
Agilent Technologies has entered into an alliance with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), to promote and develop cooperation in biotechnology.
Agilent Technologies has entered into an alliance with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), to promote and develop cooperation in biotechnology. The bodies will focus on the establishment of a global reference research lab and the development of human capital. The lab will develop global Halal testing standards in pharmaceuticals and nutraceuticals. It will also provide access to state-of-the-art analytical tools and expertise to develop the local industry and a small and medium enterprise ecosystem in their commercialization efforts.
“Agilent shares a common desire with the Government of Malaysia to realize the national agenda for biotechnology,” said Gooi Soon Chai, president of Agilent Technologies Malaysia and Singapore. “Our partnership presents an enormous potential to accelerate the development of this field as the next engine of growth for the country.”
“Through collaboration with Agilent, the Global Reference Research Lab will help intensify IPHARM’s research activities in pharmaceuticals and nutraceuticals,” said Dato’ Dr Sharifah Zarah Syed Ahmad, Deputy Secretary General of the Ministry of Science, Technology and Innovation. “This is where the local SMEs will also be able to grow their capabilities and compete on a global stage.”
For more information visit www.agilent.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
